摘要
Abstract
ObjectiveTo investigate the clinical efifcacy and safety of pancreatic kallikrein for the treatment of hypertension with microalbuminuria.Method78 cases of hypertension patients with microalbuminuria in our hospital from January 2012 to January 2014 were collected and randomly divided into observation group and control group, 39 cases in each group. Control group received conventional treatment of hypertension, observation group received pancreatic kininogenase treatment on the basis of control group, the therapeutic effects and adverse reactions of two groups were compared.ResultAfter treatment, the SBP and DBP of two groups were signiifcantly decreased than before treatment (P<0.05), but had no signiifcant difference between two groups (P>0.05); the morning urine A/C, UAER, MAU and plasma ET-1 in observation group were signiifcantly lower than control group, and plasma NO level was signiifcantly higher than control group (P<0.05); the adverse reactions rate of observation group was 7.69%, had no significant difference with control group (5.13%) (P>0.05).ConclusionPancreatic kininogenase in treatment of hypertension with microalbuminuria can reduce albuminuria, improve endothelial function and clinical outcomes, with less adverse reaction, it is safe and reliable, should be widely applied.关键词
高血压/微量白蛋白尿/胰激肽原酶Key words
Hypertension/Microalbuminuria/Pancreatic kallikrein
